review

When people mention modern medicine, accuracy plays one of the most important roles and human lives are directly dependent on it. Hence, any researches related to medicine are required to comply with the highest standards. The challenge today is that any outcomes of researches can be posted online and used as a reference without being precisely checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and attempted to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That assists both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with respective scores higher than 100

The cover for issue 30 of Oncotarget features Figure 4, "RNAseq results demonstrating differences between normal, cancer, and redirected cells," by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. Here using in vivo and in vitro models the Oncotarget authors demonstrate the impact epithelial cells and the mammary microenvironment can exert on breast cancer cells. Under specific conditions, signals that originate in epithelial cells can induce phenotypic and genotypic changes in cancer cells. The authors have termed this phenomenon “cancer cell redirection.” Once breast cancer cells are redirected, either in vivo or in vitro, they lose their tumor forming capacity and undergo a genetic expression profile shift away from one that supports a cancer profile towards

When people refer to contemporary medicine, precision plays one of the most significant roles and human lives are directly dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the top standards. The problem nowadays is that any results of researches can be shared online and used as a reference without being adequately verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality measure. That allows both readers and authors to validate publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with corresponding s

  Oncotarget recently published "Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness" which reported, that to determine if pharmacologically targeting mitochondrial dysfunction via treatment with the mitochondria-targeting peptide SS-31 would prevent cardiorespiratory muscle dysfunction, colon 26 adenocarcinoma tumor-bearing mice were administered either saline or SS-31 daily following inoculation. C26 mice treated with saline demonstrated greater ROS production and mitochondrial uncoupling compared to C26 mice receiving SS-31 in both the heart and diaphragm muscle. In addition, saline-treated C26 mice exhibited a decline in left ventricular function which was significantly rescued in C26 mice treated with SS-31. In the diaphragm, muscle fiber cross-sectional area of C26 mice treated with saline was significantly reduced and force production was impaired compared to C26

When people speak of contemporary medicine, accuracy plays one of the most crucial roles and human lives are literally dependent on it. Hereby, any researches pertaining to medicine are necessary to meet the highest standards. The challenge today is that any conclusions of researches can be shared online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and attempted to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That allows both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a full publications list with respective scores above 100 as well

When people refer to today’s medicine, accuracy plays one of the most significant roles and people’s lives are literally dependent on it. Hence, any researches pertaining to medicine are necessary to meet the highest standards. The problem nowadays is that any outcomes of researches can be posted online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and attempted to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality measure. That allows both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website has a full publications list with corresponding scores above 100 as well

 The cover for issue 38 of Oncotarget features Figure 3, "Summary of the time and cost for drug development (modified from DiMasi et al [2016]," by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies. In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies. In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies. Studies were curated and categorized according to the phase of the study, the clinical stage of the study population, type of intervention under investigation, and biologic mechanism targeted by the therapy under study. As of May 18, 2019, there were 430 total active therapeutic interventional trials testing 590 int

When public refer to today’s medicine, precision plays one of the most significant roles and human lives are directly dependent on it. Hereby, any researches related to medicine are necessary to comply with the top standards. The challenge today is that any conclusions of researches can be posted online and used as a reference without being properly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and tried to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with corresponding scores above 100

Oncotarget recently published "Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer" which reported that unfortunately, a significant portion of NSCLC patients relapse due to cisplatin chemoresistance. Administration of hemoglobin-based oxygen carriers is a promising strategy to alleviate hypoxia in the tumor, which may make cisplatin more effective. The R-state PolyHb administered in this study is unable to deliver O2 unless under severe hypoxia which significantly limits its oxygenation potential. In vitro sensitivity studies indicate that the administration of PolyHb increases the effectiveness of cisplatin under hypoxic conditions. Additional animal studies revealed that co-administration of PolyHb with cisplatin attenuated tumor growth without alleviating hypoxia. Additional animal studies revealed that co-administration of PolyHb with cisplatin attenuated tumor growth without alleviating hypoxia Dr

When general population speak of modern medicine, accuracy plays one of the most significant roles and human lives are directly dependent on it. Hence, any researches related to medicine are necessary to meet the highest standards. The challenge today is that any outcomes of researches can be published online and used as a reference without being adequately verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and tried to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is based on Altmetric scores that are used as a quality indicator. That helps both readers and authors to quality-check publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with corresponding sco

When public refer to contemporary medicine, precision plays one of the most important roles and people’s lives are literally dependent on it. Hereby, any researches pertaining to medicine are required to comply with the top standards. The issue nowadays is that any conclusions of researches can be posted online and used as a reference without being properly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and attempted to generate an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality measure. That assists both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website has a full publications list with respective scores above 100 as well